Article http://dx.doi.org/10.26855/ijcemr.2023.10.008

Drug Reposition: The Analysis of the Possibility of Using Aspirin for the Prevention of Cancers


Wanjun Jin

Qitaihe No. 1 Middle School, Qitaihe, Heilongjiang, China.

*Corresponding author: Wanjun Jin

Published: November 30,2023


Aspirin is one of the oldest medicines that humans have used to treat a wide range of diseases. A good example is its use in the prevention of various tumors. Past studies have identified 11 types of cancer can be prevented by using aspirin. Within the past few decades, researchers have identified the mechanism through which aspirin prevents the development of cancer. Spe-cifically, researchers have found out that it has the potential to influence how cyclooxygenase-2(COX-2) is expressed in the body and its product, prostaglandin E2 (PGE2). These two compounds, COX-2 and PGE2, are essential in dictating the process of tumor cells. Past studies focusing on patients' health outcomes have also revealed that aspirin has the potential to influence the progression of cancer. However, there are limitations regarding the study and role of aspirin, such as side effects and inadequacy in research. Nonetheless, the progress of aspirin on a wide range of cancers continues to enhance patients' medical experiences and outcomes. This research reviewed several clinical trials related to aspirin and various types of cancers and analyzed the potential application of aspirin in cancer prevention. Several limitations, including the side effects of aspirin, appropriate dosage, and research constraints, have been taken into account.


[1] Giovannucci E, et al. (1996). Aspirin and the risk of colorectal cancer in women [J]. N Engl J Med, 334(2): 121-122. [Accessed 4 December 2021]
[2] Peter M Rothwell, et al. (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials [J]. Lancet, 377. [Accessed 4 December 2021]
[3] Rothwell P M, et al. (2012). Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials [J]. Lancet, 379(9826). [Accessed 4 December 2021]
[4] Yin C, et al. (2015). Long-term use of aspirin and risk of cancer [J]. Cancer Research, 75:876-876. [Accessed 4 December 2021]
[5] Choi J, et al. (2016). Aspirin use and the risk of cholangiocarcinoma [J]. Hepatology, 64(3). [Accessed 4 December 2021]
[6] Brandi G, et al. (2016). Aspirin for cholangiocarcinoma prevention: new targets to shift the dogma from ascertained risk to possible prevention (Reply to: Risk Factors for Cholangiocarcinoma: Aspirin-use and the Risk of Cholangiocarcinoma) [J]. Hepatology, 65(3):1075. [Accessed 4 December 2021]
[7] Ferlay J, et al. (2012). Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. [Accessed 30 November 2021]

How to cite this paper

Drug Reposition: The Analysis of the Possibility of Using Aspirin for the Prevention of Cancers

How to cite this paper: Wanjun Jin. (2023) Drug Reposition: The Analysis of the Possibility of Using Aspirin for the Prevention of Cancers. International Journal of Clinical and Experimental Medicine Research7(4), 567-572.

DOI: http://dx.doi.org/10.26855/ijcemr.2023.10.008